Sanofi courts AstraZeneca CEO Soriot; Teva CEO optimistic on Copaxone patent ruling; AstraZeneca scores approval of diabetes combo drug.
Herper writes that Sanofi—without Viehbacher—is at risk of moving too slowly in an increasingly competitive industry.
Sanofi CEO fired; Sovaldi sales slow; Ranbaxy CEO affirms generic Nexium rights.
Despite the Treasury's crackdown on inversions, CEO Ian Read says they would still invert for the right deal.
The drugmaker plans to cut 600-1,100 jobs next year.
Sanofi is expected to slash prices of its diabetes products to retain US market access.
With Ranbaxy's failure to launch a low-cost version of the acid reflux drug, pressure is mounting on FDA to speed a generic to market.
Sanofi CEO says diabetes sales will slow in 2015; Takeda/Lilly Actos settlement slashed by 99%; study says Sovaldi is cost-effective for prisoners.
The drug is now expected to be filed by mid-2015, rather than by year's end.
The drugmaker's pharma sales fell by 4%, even as Merck's Keytruda cancer darling received another Breakthrough Therapy designation.
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.